Fezolinetant Patent Expiration
Fezolinetant is Used for managing moderate to severe vasomotor symptoms associated with menopause. It was first introduced by Astellas Pharma Us Inc
Fezolinetant Patents
Given below is the list of patents protecting Fezolinetant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Veozah | US10836768 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Mar 28, 2034 | Astellas |
| Veozah | US9422299 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Mar 28, 2034 | Astellas |
| Veozah | US9987274 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Mar 28, 2034 | Astellas |
| Veozah | US8871761 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | Apr 04, 2031 | Astellas |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fezolinetant's patents.
Latest Legal Activities on Fezolinetant's Patents
Given below is the list recent legal activities going on the following patents of Fezolinetant.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 May, 2024 | US10836768 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US9987274 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US10836768 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US9422299 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Feb, 2024 | US9422299 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US9422299 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US10836768 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US9987274 |
| Letter re PTE application to FDA or Dept of Agriculture | 29 Sep, 2023 | US10836768 |
| Letter re PTE application to FDA or Dept of Agriculture | 29 Sep, 2023 | US9422299 |
Fezolinetant's Family Patents
